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E-mail: axheczey@txch.orgTargeting disialoganglioside (GD2) on neuroblastoma (NB)
with T cells expressing a first-generation chimeric antigen re-
ceptor (CAR) was safe, but the cells had poor expansion and
long-term persistence. We developed a third-generation GD2-
CAR (GD2-CAR3) and hypothesized that GD2-CAR3 T cells
(CARTs) would be safe and effective. This phase 1 study
enrolled relapsed or refractory NB patients in three cohorts.
Cohort 1 received CART alone, cohort 2 received CARTs
plus cyclophosphamide and fludarabine (Cy/Flu), and cohort
3 was treated with CARTs, Cy/Flu, and a programmed death-1
(PD-1) inhibitor. Eleven patients were treated with CARTs.
The infusions were safe, and no dose-limiting toxicities
occurred. CARTs were detectable in cohort 1, but the lympho-
depletion induced by Cy/Flu increased circulating levels of the
homeostatic cytokine interleukin (IL)-15 (p = 0.003) and
increased CART expansion by up to 3 logs (p = 0.03). PD-1 in-
hibition did not further enhance expansion or persistence.
Antitumor responses at 6 weeks were modest. We observed a
striking expansion of CD45/CD33/CD11b/CD163+ myeloid
cells (change from baseline, p = 0.0126) in all patients, which
may have contributed to the modest early antitumor responses;
the effect of these cells merits further study. Thus, CARTs are
safe, and Cy/Flu can further increase their expansion.
INTRODUCTION
The disialoganglioside (GD2) is universally expressed on melanoma,
lung cancer, and neuroblastoma (NB) and found on few healthy tis-
sues. Immunotherapeutic targeting of GD2 with monoclonal anti-
bodies (ch14.18) has significantly improved event-free survival of
high-risk NB patients,1,2 and it was recently incorporated in the stan-
dard care for these patients. Nonetheless, treatment may still be inef-
fective and is associated with significant toxicities.1
An alternative immunotherapeutic approach is to express chimeric
antigen receptors (CARs) targeting the same validated GD2 antigen
on effector T cells.3 CAR-based immunotherapy can combine the2214 Molecular Therapy Vol. 25 No 9 September 2017 ª 2017 The Amspecificity of a monoclonal antibody (mAb) with the effector func-
tion, active biodistribution, and long-term persistence of T cells.4
CAR T cells can produce a high rate of sustained complete remission
(CR) in patients with hematologic malignancies even when the dis-
ease is advanced.5
In a previous study, we compared the effects of activated T cells
(ATCs) and Epstein-Barr virus-specific cytotoxic T cells (EBVSTs),
both of which expressed a first-generation GD2-CAR (i.e., one that
lacks embedded costimulatory signaling domains) in relapsed and
refractory NB patients. We found that cells were well tolerated, and
3 of 11 treated patients entered CR.3,6 Because the infused ATCs
and EBVSTs expressed genetically distinguishable first-generation
CARs, we could also show that initial persistence was greater in the
CAR-VST population than in CAR-ATCs. We proposed that the su-
periority of CAR-VSTs might be attributable to the physiologic cos-
timulation received during engagement of their native, virus-specific
TCRwith the professional antigen-presenting cells (APCs) expressing
viral antigens that are found in EBV-seropositive recipients. For the
current clinical study, we determined whether we could compensate
for the lack of physiologic costimulation in GD2-CAR ATC by
substituting a next-generation CAR that incorporated its own costi-
mulatory signals. In preclinical studies, we found that a third-gener-
ation GD2-CAR incorporating both the CD28 and the OX40
costimulatory endodomains (GD2-CAR3) provided ATC with the
greatest antitumor activity,7 and here we report the results of a clinical
study using this CAR in patients with relapsed or refractory NB.
The aim of this study testing a third-generation CAR with CD28 and
OX40 costimulatory endodomains was to define the feasibility, safety,erican Society of Gene and Cell Therapy.
Figure 1. Flow Chart of Clinical Trial NCT01822652
Black arrow indicates GD2-CAR3 T cells expanded with IL-2 and administered after
a freezing step. Yellow arrows indicate conditioning with cyclophosphamide
500mg/m2/dose on days4,3, and2 and fludarabine 30mg/m2/dose on days
4 and 3. Green arrows indicate GD2-CAR3 T cells expanded with IL-7/15 and
administered without a freezing step. Blue arrows indicate PD-1 inhibitor, pem-
brolizumab, given at 2 mg/kg/dose on days 1 and 21. Response to therapy
evaluation was completed with 3D imaging (bone marrow testing when applicable)
on week 6.
www.moleculartherapy.organd persistence of GD2-CAR3 T cells with or without conditioning
and programmed death-1 (PD-1) inhibition. Thus, we used an
adaptive-design phase 1 clinical trial with three cohorts, all receiving
autologous GD2-CAR3 T cells (Figure 1). In cohort 1, we infused
escalating doses of GD2-CAR3 T cells alone. In cohort 2, to improve
the expansion and persistence of GD2-CAR3 T cells, we gave condi-
tioning with cyclophosphamide and fludarabine (Cy/Flu) prior to cell
infusions;8 whereas in cohort 3, to overcome the immunosuppressive
effect of the tumor microenvironment, we combined Cy/Flu with two
doses of PD-1 antibody.9
RESULTS
Patient Characteristics and Study Cohorts
Eleven patients (eight female, three male) with a median age of
6.5 years (range 4.1–23.6 years) with relapsed or refractory NB
were enrolled, and all were infused with GD2-CAR3 T cells. All
patients had active disease at the time of the infusions; all clinical
characteristics are in Table 1. According to the International Neuro-
blastoma Staging System,10 1 patient had an unresectable, stage 3 pel-
vic tumor and 10 patients had stage 4 (metastatic) disease; bone and
bone marrow were the most common metastatic sites. All patients
had response to therapy assessment at week 6 (day 42) post-CAR
T cell infusion (Table 1).
Safety of Infusions
All GD2-CAR3 infusions were well tolerated, and none of the patients
had any immediate reactions at the time of administration. No dose-
limiting toxicities were observed. Similar numbers of febrile episodes
were detected in all cohorts (2, 1, and 2 in cohorts 1, 2, and 3, respec-
tively), and fever and neutropenia were seen in one patient from both
cohorts 2 and 3. There was one episode of cytokine release syndrome
(CRS) in patient 1C, but this did not exceed grade 2 and required only
prophylactic antibiotics. The episode resolved spontaneously by day 7
after presentation (Table 2).Conditioning with Cy/Flu Prior to Adoptive Transfer Is
Associated with Increased GD2-CAR3 T Cell Expansion
To assess the effect of Cy/Flu on the incidence of hematologic compli-
cations, we compared cohort 1 (without Cy/Flu) with cohorts 2 and 3
(with Cy/Flu) and found that, while patients in all three cohorts may
develop hematologic side effects, grades 3 and 4 leukopenia, lympho-
penia, neutropenia, and thrombocytopenia were seen less commonly
in cohort 1 compared with cohorts 2 and 3 (grades 3 and 4 leukopenia:
0 versus 7; lymphopenia: 1 versus 7; neutropenia: 1 versus 6; and
thrombocytopenia 0 versus 5; all hematologic side effects cohort 1
versus cohorts 2 and 3: p < 0.001, Fisher’s exact test). There were no
significant neurologic complications in any cohort and in particular
no episodes of severe pain or other CNS-related side effects previously
reported with CAR T cells targeting other antigens.8,11 Two patients
had transient, spontaneously resolving paresthesias.
At the time of study entry, patients had highly variable peripheral
white blood cell counts (WBCs; median 3.91 cells  103/mL, range
2.31–6.37 cells 103/mL). After Cy/Flu, theirWBC decreased (median
2.99 cells 103/mL, range 0.31–4.44 cells 103/mL; Figure S1), and pa-
tients were profoundly lymphopenic at the time of CAR T cell infu-
sions (absolute lymphocyte count [ALC]/mL blood; cohort 1: median
1,367 [range 640–2,276] versus cohorts 2 and 3 [with lymphodeple-
tion]: median 49 [range 9–111]) (Figure 2A). During the first 6 weeks
of toxicity and response to therapy assessment, we detected signifi-
cantly increased expansion of GD2-CAR3 T cells in patients in cohorts
2 and 3, as indicated by a rise in the copy number of the CAR transgene
per milliliter of peripheral blood from 4 hr post-infusion to week 1 and
week 4 time points (p = 0.011 and 0.018, respectively, Wilcoxon rank-
sum test) and by the area under the curve (AUC) of copy number per
milliliter over time (cohort 1: median 2,190 [range 978–8,736.1] versus
cohorts 2 and 3: median 13,561.5 [range 3,100.2–184,607.5]; p = 0.03).
The differences between cohorts diminished by week 6 (Figure 2B; Fig-
ure S2A). A CAR+ T cell population could be detected by FACS anal-
ysis only in the most highly PCR-positive patients (shown for patient
2A in Figure S2B). GD2-CAR3 T cells could be detected by PCR at low
levels 1 year after adoptive transfer even after most patients received
salvage lymphotoxic chemotherapy after completing therapy on this
study (Figure 2C; separated data for each patient, Figure S2C).
Of note, the expansion and persistence of GD2-CAR3 T cells in
cohort 3, who received PD-1 blocking antibody, was no greater
than that observed in cohort 2 (no PD-1). PD-1 expression on the
infused cells was low on CAR T cells (CD4 subset: median 20.4%,
range 18.8%–20.6%; CD8 subset: median 5.23%, range 3.38%–
9.04%; Figure S3) prior to infusion. Although the level could increase
after CAR T cell activation in the tumor, the low PD-1 expression at
baseline may explain why the addition of PD-1 inhibition did not
show any detectable change in CAR T cell expansion and survival.
Higher Circulating IL-15 Levels Are Associated with Increased
GD2-CAR3 T Cell Expansion
Next, we explored whether increased CAR T cell expansion was asso-
ciated with a change in circulating levels of homeostatic cytokines.Molecular Therapy Vol. 25 No 9 September 2017 2215
Table 1. Patient Characteristics and Study Cohorts
Cohort Patient ID Age (Years) Gender INSSa Involved Sites Dose Cy/Flub PD-1 Inhibitorc
1
1A 23.6 M 4 multifocal bone and bone marrow 1  107 no no
1B 5.7 M 4 multifocal bone, liver, bone marrow 1  107 no no
1C 4.7 F 4 multifocal bone, lymph node, bone marrow 1  108 no no
1D 22.5 F 4 single skull lesion 1  108 no no
2
2A 8.5 F 4 single bone lesion 1  108 yes no
2B 7.4 F 4 multifocal bone, lymph node, bone marrow 1  108 yes no
2C 6.5 F 4 single bone lesion 1.5  108 yes no
2D 4.1 F 4 multifocal bone and bone marrow 1.5  108 yes no
3
3A 6.9 M 4 multifocal bone and bone marrow 1.5  108 yes yes
3B 5.0 F 4 multifocal bone and bone marrow 1.5  108 yes yes
3C 5.0 F 3 single soft tissue mass 1.5  108 yes yes
GD2-CAR3 T cell dose calculated as CAR+ T cells/m2 of body surface area. INSS, International Neuroblastoma Staging System.10
aAt the time of CAR T cell infusion.
bCyclophosphamide 500 mg/m2/dose on days 4, 3, and 2 and fludarabine 30 mg/m2/dose on days 4 and 3 intravenously.
cPD-1 inhibitor: pembrolizumab given on days 1 and 21 at 2 mg/kg/dose intravenously.
Molecular TherapyOne patient (patient 2C) was enrolled after tandem high-dose meta-
iodobenzylguanidine (MIBG) and had a sustained and broad increase
in multiple pro-inflammatory cytokine levels (including interleukin
[IL]-15) throughout the study period. Patient 2C was therefore
excluded from this analysis (Figure S4A). In cohorts 2 and 3
(receiving Cy/Flu), we detected higher IL-15 levels at the time of
CAR T cell infusion than in cohort 1 (with Cy/Flu: mean
4.27 pg/mL, SD: 2.59; with Cy/Flu: mean 43.25 pg/mL, SD: 18.26;
p = 0.003) (Figure 2D) and larger AUC of IL-15 over time in cohorts
receiving Cy/Flu (cohort 1: mean 4.27 pg/mL, SD: 2.59; cohorts 2
and 3: mean 43.24 pg/mL, SD: 18.25; p = 0.005) (Figure 2E). No
differences were detected in other homeostatic cytokine levels in
patients, including IL-2 and IL-7 (data not shown). Importantly,
higher circulating IL-15 levels correlated with increased GD2-CAR3
T cell expansion as judged by Spearman correlation (r = 0.796; p =
0.006) (Figure 2F). There was no generalized cytokine release associ-
ated with this treatment because serum interferon-g (IFN-g), IL-6,
and tumor necrosis factor alpha (TNF-a) remained low (Figures
S4B–S4D).
M2 Macrophage-like Myeloid Subset CD45/CD33/CD11b/
CD163+ Expands in Peripheral Blood of Patients Treated with
GD2-CAR3 T cells Irrespective of Mononuclear Cell Depletion
with Cy/Flu
Wealso analyzed the effects of treatment on thephenotype andkinetics
of myeloid subsets during the initial 6-week follow-up period in all pa-
tients. The change in the absolute monocyte count (AMC) is shown in
Figure S5. We examined whether the change in monocytes correlated
with an increase in myeloid subsets with potential immunoinhibitory
properties. Although there was no change in the CD45/CD11b/
CD33+, CD15/human leukocyte antigen (HLA)-DRmyeloid-derived
suppressor cell-like (MDSC-like) subsets before or after CAR T cell in-
fusions (Figures 3A and3B),we detected amarked increase in cellswith
an M2-associated phenotype (CD45/CD33/CD11b/CD163+) in all2216 Molecular Therapy Vol. 25 No 9 September 2017patients in all cohorts after infusion of CART cells (one detailed repre-
sentative in Figure 3C; all are summarized in Figures 3D and 3E). At
baseline (within 96 hr prior to CAR T cell infusion), the percentage
of cells in the CD45/CD33/CD11b/CD163+ myeloid subset was low
(approximately 0.01%); however, the percentage of this population
increased significantly after CART cell infusions irrespective of cohort
(week 1: median 3.15%, range 1.97%–13.27%; week 2: median 4.41%,
range 0.77%–14.79%; week 4: median 1.78%, range 0.01%–9.73%;
week 6: median 0.825%, range 0.01%–4.23%; p = 0.0126, Wilcoxon
signed rank test, p values reflect comparisonwith baseline) (Figure 3D).
Independent of Cy/Flu or PD-1 inhibition, a striking expansion of
the absolute number of thesemyeloid cells was also detected, exceeding
100 cells/mL in some patients (week 1: median 9.86 cells/mL, range
2.41–56.68 cells/mL; week 2: median 22.4 cells/mL, range 2.76–152.23
cells/mL; week 4: median 6.89 cells/mL, range 0.04–42.13 cells/mL;
p = 0.0126, Wilcoxon signed rank test, p values reflect comparison
with baseline) (Figure 3E). The appearance of CD45/CD33/CD11b/
CD163+ myeloid subset in the peripheral blood thus occurs indepen-
dent of changes in the MDSC-like population or of administration of
Cy/Flu.
Clinical Responses after GD2-CAR3 T Cell Infusions
We measured disease burden pre- and post-infusion as detailed in the
Materials andMethods, and response to therapy was evaluated accord-
ing the International Neuroblastoma Response Criteria and Curie
scoring.10 Clinical responses are summarized in Table 3. Of the 11
evaluable patients, 6 had progressive disease (PD) and 5 had stable dis-
ease at 6-week follow-up. For patients who received more than one
infusion, the best response (measured 6 weeks after each infusion)
was seen after the first infusion. Among patients with stable disease,
patient 3A achieved a CR after his salvage regimen. After two re-infu-
sions of GD2-CAR3 T cells, patient 3C had a small residual pelvicmass
that was resectable after therapy and the patient remains in CR. Addi-
tional response to therapy evaluation by comparing the number of
Table 2. Safety Assessment of GD2-CAR3 T Cells
Grade
Cohort 1 Cohort 2 Cohort 3 All Cohorts
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
Inflammation Related
Fever 1 1 1 2 3 2
Fever and neutropenia 1 1 2
CRS 1 1
Total 2 1 1 1 2 1 4 2 2
Hematologic
Anemia 2 1 1 1 2 1 1 1 4 4
Leukopenia 1 1 3 2 1 3 4
Lymphopenia 1 1 4 3 1 7
Neutropenia 1 2 2 1 1 1 3 3
Thrombocytopenia 1 2 2 1 1 2 3
Total 4 2 2 0 1 1 7 11 1 1 4 6 6 13 17
Neurologic
Arthralgia 1 1
Extremity pain 2 2
Paraesthesia 2 2
Lymph node pain 1 1
Facial pain 1 1
Headache 1 1 2
Back pain 1 1 2
Bone pain 1 1
Abdominal pain 2 2
Pelvis pain 1 1
Neck pain 1 1
Total 4 4 2 6 10 4 2
Grading according to the Common Terminology Criteria for Adverse Events version 4.0 (CTCAEv4). CRS, cytokine release syndrome.
www.moleculartherapy.orgMIBG avid lesions before and after infusions was available for eight pa-
tients. Curie scores increased in four patients, remained stable in one
patient, and improved in three patients (Figure 4A). Lastly, we evalu-
ated the long-term survival of patients treated with GD2-CAR3 T cells.
The median survival for all patients was 506 days, with seven patients
alive in long-term follow-up. All four patients in cohort 1 progressed
and died at 32–506 days (median 230 days). By contrast, six of seven
patients in the lymphodepleted treatment cohorts (2 and 3) survive
at >265 to >724 days (median survival [MS] not reached), and two
of these subjects (in cohort 3) achieved CR as described earlier. Sur-
vival curves for all patients and for patients in cohort 1 versus cohorts
2 and 3 are shown in Figures 4B and 4C, respectively.
DISCUSSION
We report a phase 1 study of autologous T cells expressing a third-
generation GD2-specific CAR conducted with adaptive trial design
to evaluate the stepwise addition of Cy/Flu and PD-1 inhibition to
CAR T cells in three consecutive relapsed or refractory NB patient co-horts. GD2-CAR3 T cell infusions were administered with or without
Cy/Flu conditioning and two peri-infusion doses of PD-1 antibody to
NB patients and were well tolerated in all cohorts. We found that Cy/
Flu increases the expansion of GD2-CAR3 T cells after adoptive
transfer, an effect that is not further modified by addition of peri-infu-
sion PD-1 blockade. We detected striking expansion of circulating
CD45/CD33/CD11b/CD163+ M2 macrophage-like myeloid cells in
all patients after CAR T cell infusions irrespective of lymphodeple-
tion. Five of 11 patients had stable disease at 6-week response assess-
ment, and patients went on to individualized salvage chemotherapy.
All four patients in cohort 1 progressed and died at 32–506 days (me-
dian 230 days), whereas six of seven patients in the lymphodepleted
treatment cohorts (2 and 3) survive at >265 to >724 days (MS not
reached), and two of these subjects (both in cohort 3) achieved CR.
Our evaluation of GD2-CAR3 T cells showed safety, even when the
cells expand and persist in vivo. Although administration of Cy/Flu
increased grades 3 and 4 hematologic side effects, and two patientsMolecular Therapy Vol. 25 No 9 September 2017 2217
Figure 2. Expansion and Persistence of GD2-
CAR3 T Cells after Adoptive Transfer
Peripheral blood evaluation of patients infused with GD2-
CAR3 T cells at indicated time points. (A) Absolute
lymphocyte count (Ly/mL). (B) Expansion of GD2-CAR3
T cells in patients in cohort 1 (black) or cohorts 2 and 3
(purple) prior to week 6 response to therapy evaluation by
real-time PCR; transgene copy numbers per milliliter.
Lines represent median. (C) Long-term persistence of
GD2-CAR3 T cells in patients treated in cohort 1 (black) or
cohorts 2 and 3 (purple). (D) Peak IL-15 levels (pg/mL) in
patients detected on the day of CAR T cell infusions with
(cohorts 2 and 3) and without lymphodepletion (cohort 1)
measured by Luminex assay. Mean with SD. (E) Periph-
eral blood IL-15 levels (pg/mL) in patients in cohort 1
(black) or cohorts 2 and 3 (purple). Line represents me-
dian. (F) Association of area under the curve (AUC) of
GD2-CAR3 T cells’ expansion until response to therapy
evaluation at week 6 and peak IL-15 levels. (A and D)
Patients in cohort 1 are represented in black, cohort 2 in
green, and cohort 3 in blue; each patient per cohort is
represented by a different shape. ***p < 0.001, t test.
Molecular Therapydeveloped febrile neutropenia, this was an anticipated and manage-
able consequence of the drugs’ myelosuppressive effects.
In terms of CAR T cell-associated toxicities, only one patient devel-
oped CRS, which resolved spontaneously without corticosteroid or
anti-IL-6 treatment. CRS was not observed even in patients in
whom CAR T cells in peripheral blood expanded comparably with
successful CD19-CAR T cell studies.8,12 Because CRS can be associ-
ated with response to therapy,8,11 it is possible that its incidence
will increase if more potent GD2-CAR therapies are developed. Alter-
natively, the prevalence and severity of CRS may be more dependent
on the cell population targeted than on the effector cells per se. Thus,
CD19-specific effector cells target normal and malignant B cell pop-
ulations that serve as antigen-presenting cells and express an array of
costimulatory molecules that enhance T cell activation.13 By contrast,
the lack of costimulatory molecules on NB14 may limit T cell activa-2218 Molecular Therapy Vol. 25 No 9 September 2017tion in response to antigen and reduce the likeli-
hood of CRS. Additionally, the tumor microen-
vironment in NB contains myeloid cells,
particularly M2 polarized tumor-associated
macrophages (M2 TAMs), with immunosup-
pressive properties15 that may further diminish
T cell activation and reduce the release of
pro-inflammatory cytokines. Moreover, we
observed no CNS toxicities of the type associ-
ated with CD19-CAR T cell infusions, which
may occur independently of CRS. The mecha-
nisms that underlie these neurotoxicities are
poorly understood but have been asserted to
be exacerbated by Cy/Flu.5 In our study, seven
patients received Cy/Flu without CNS-related
side effects, notwithstanding substantial expan-sion of CAR T cells in peripheral blood.8,12 Thus, the neurotoxicities
of the Cy/Flu combination, like CRS, may be CAR target specific
rather than generalizable for the combination of lymphodepleting
drugs and subsequent CAR T cell engraftment.
Of note, targeting GD2 with CAR T cells did not produce the painful
peripheral neurotoxicity that is often associated with administration
of GD2-specific monoclonal antibodies (mAbs).1,2 Instead, the inci-
dence and severity of pain-related side effects after GD2-CAR3 T cells
remained as low as in our previous reports, even though GD2-CAR3
T cells exhibited greater expansion.3 The frequent and severe pain
noted in patients receiving GD2-specific mAbs1,2 is attributed to
the presence of moderate levels of the targeted antigen within pain re-
ceptors on sensory nerves and within the dorsal horns of the spine.16
The mechanisms by which GD2 mAbs initiate pain remain contro-
versial, although complement fixation is thought to contribute.17
Figure 3. Change of Peripheral Blood Myeloid Subsets after GD2-CAR3 T Cell Infusion
Peripheral blood myeloid subset composition was analyzed with multiparametric flow cytometry at indicated time points. (A) Kinetics of CD45/CD33+, HLA-DR/CD15
peripheral bloodmyeloid-derived suppressor cell-like (MDSC-like) subset as percentage of peripheral bloodmonocytes. (B) Absolute number of MDSC-like myeloid subset in
peripheral blood per microliter. (C) Appearance of CD45/CD33/CD11b/CD163+ myeloid subset in a representative patient after GD2-CAR3 T cell infusion. (D) Kinetics of
CD45/CD33/CD11b/CD163+ peripheral blood myeloid cell subset as percentage of peripheral blood monocytes. (E) Absolute number of CD45/CD33/CD11b/CD163+
peripheral bloodmyeloid cell subset per microliter. Patients in cohort 1 are represented by black shapes, cohort 2 by green shapes, and cohort 3 by blue shapes. Each shape
and color combination represents a patient. *p < 0.05, t test.
www.moleculartherapy.org
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Table 3. Response to Therapy after Infusion with GD2-CAR3 T Cells










1A stable disease 1 stable disease DOD 172
1B PD 1 PD DOD 288
1C PD 1 PD DOD 32
1D stable disease 2 PD stable disease DOD 506
2
2A PD 1 PD AWD 724
2B PD 1 PD DOD 265
2C stable disease 2 PD stable disease AWD 710
2D PD 1 PD AWD 656
3
3A stable disease 2 stable disease stable disease CR 535
3B PD 1 PD AWD 524
3C stable disease 3 stable disease stable disease CR 500
AWD, alive with disease; DOD, died of disease; PD, progressive disease.
Molecular TherapyThe lack of toxicity from CAR T cells may therefore be attributed to
lack of CAR-expressing cell access to the pain receptors or to lack of
the required effector mechanisms. It therefore remains a concern that
increasing CAR T cell expansion or modifying T cell trafficking or
effector activity will concomitantly trigger severe neurogenic pain;
our inclusion of an inducible suicide gene (inducible caspase-9
[iC9]) in this and future GD2-CAR constructs is intended to allow
us to mitigate the consequences should such neurotoxicity develop.18
Our study confirmed that lymphodepletion can substantially increase
the in vivo expansion of the infused cells.8,19–21 Administration of con-
ditioning therapy has multiple effects, by reducing the patient’s
lymphoid cell pool, increasing homeostatic cytokines, and ameliorating
the tumor inhibitory microenvironment.20,22,23 We confirmed the
beneficial effects of lymphodepletion on CAR T cell engraftment and
found that increased peripheral blood IL-15 levels after Cy/Flu corre-
late with GD2-CAR3 T cell expansion. The superior expansion of
CAR T cells after Cy/Flu may also have been facilitated by the lack of
cryopreservation prior to cell infusion or the substitution of IL-7/15
for IL-2 during manufacture, a modification made primarily to accel-
erate T cell expansion24 for patients in cohorts 2 and 3. The phenotype
of the infused cells was unaffected by this change (Figure S6), which
may be the result of tonic signaling associated with GD2-CARs.25
The benefits of lymphodepletion that have previously been reported
for second-generation CAR T cells can therefore also be obtained for
third-generation CAR T cells in which both CD28 andOX40 costimu-
latory domains are present.20,22 Positive effect of IL-15 on the expan-
sion of CAR T cells reported here and shown by others may be utilized
to enhance adoptive cell therapies by systemic IL-15 or IL-15 supera-
gonist administration; however, careful dosing of the effector cells
and IL-15 or its superagonist will be important to avoid toxicities.26–28
PD-1 could be detected on GD2-CAR3 T cells, and GD2-CAR3 T
cells produce IFN-g after CAR-mediated activation, which can upre-
gulate PD ligand-1 (PD-L1) expression on NB cells (Figure S7). Given2220 Molecular Therapy Vol. 25 No 9 September 2017that inhibiting the deleterious PD-1–PD-L1 interaction can improve
the antitumor activity of CARs,9,29 we administered two doses of the
PD-1 inhibitor pembrolizumab to patients in cohort 3 on days 1
and +21 of GD2-CAR3 T cell infusions, although combining GD2-
CAR3 T cells with PD-1 inhibitor was feasible and safe. In our study,
pembrolizumab had no measurable effect on CAR T cell expansion,
persistence, or circulating cytokine levels. This contrasts with data
in some preclinical models and in a recent case report of a patient
treated for lymphoma, in which the combination of CAR T cells
with PD-1 inhibition improved the antitumor activity of CAR
T cells.30–32 Beneficial effects on CAR T persistence and expansion
from checkpoint blockade may depend on the timing and duration
of PD-1 inhibition or may require the presence of a greater number
of tumor neoantigens (stimulating CAR T cells through their native
TCRs) than are present in most pediatric malignancies including
NB. Although it was only in the PD-1 cohort in whom we observed
CRs after salvage therapy, no conclusions can yet be drawn from
such limited observations in such a heterogeneous group of patients.
The continued testing of checkpoint inhibitors in conjunction with
CAR T cells in more patients and in different cancers will demon-
strate whether survival benefit can indeed be obtained, even after
limited exposure to checkpoint inhibition.
One of our most striking observations was the consistent increase
in the circulating CD45/CD33/CD11B/CD163+ myeloid subset
following GD2-CAR3 T cell infusion. This effect was independent
of lymphodepletion and has not been a general observation after
administration of CAR T cells with other specificities. Inhibitory
myeloid cells are increasingly being recognized as important obstacles
to successful immunotherapy,33–35 and the presence of myeloid-
derived suppressor cells (MDSCs) or tumor-associated macrophages
(TAMs) can worsen the prognosis of patients with cancer, including
NB, and can limit the benefits of immunomodulation,36,37 and target-
ing MDSCs in preclinical NB models can have a significant antitumor
effect.38 The hemoglobin-scavenger receptor CD163 is an important
Figure 4. Outcome of Patients Treated with GD2-CAR3 T Cells
(A) Waterfall plots of the difference in Curie scores before and after therapy. (B)
Kaplan-Meier survival curves of all patients. (C) Separated survival curves for pa-
tients in cohort 1 (black) and cohorts 2 and 3 (both shown in pink).
www.moleculartherapy.orgsurface marker of M2 macrophages, and the presence of M2 markers
on TAMs is associated with poor outcome in patients with NB15 and
in many other human cancers as well. The adverse effects of M2
TAMs are likely mediated by the immune-inhibitory and anti-inflam-
matory cytokines they secrete.36 It is not feasible to sequentially sam-
ple tumor biopsies before and during CAR T cell treatment to confirmthat the dynamic changes in M2macrophage-like myeloid cells in pe-
ripheral blood were matched by equivalent changes in resident M2
TAMs. Nonetheless, the robust and consistent increase in the
numbers of M2 macrophage-like myeloid cell numbers in peripheral
blood we observe suggests that the infusion of GD2-CAR3 T cells
provokes a response from the tumor that recruits marrow-derived
monocytes and polarizes them to an M2 phenotype. If these M2
macrophage-like myeloid cells are then attracted to the tumor site
and augment the M2 TAMpopulation, it may be beneficial to develop
countermeasures to this immune evasion strategy.39
Thus, our third-generation GD2-CAR3 T cells were detected at
higher levels in NB patients compared with first-generation GD2-
CAR T cells; this advantage can be further and safely increased by
Cy/Flu treatment prior to infusion, resulting in significant, but tran-
sient, expansion of CAR T cells. Disappointingly, the immediate anti-
tumor effects of the GD2-CAR3 T cells were no greater than observed
in our earlier study of first-generation GD2-CAR T plus first-gener-
ation GD2-CAR EBVST,3,6 and the study was not powered to show
a significant benefit to survival from increased CAR T cell expansion
in cohort 1 versus cohorts 2 and 3. Because of the heterogeneity of
patients’ prior treatment, their disease status at study entry and the
individualized salvage regimens they received post-study mean that
we cannot identify which components contributed to these apparent
differences in longer-term outcome.
In the 10 years since we developed the GD2-CAR3 used here, we and
others have shown in preclinical studies that further modifications to
the antigen binding exodomain, the CAR spacer region, and the
costimulatory endodomains may substantially augment the in vivo
functionality of GD2-CAR T cells.25,29,40,41 We anticipate that a com-
bination of these modifications together with countermeasures to pre-
existing and evolving tumor immune evasion strategies, including the
dynamic evolution we detected in the myeloid compartment, will
produce both more immediate tumor responses and superior out-
comes in future clinical studies.
MATERIALS AND METHODS
Study Design
We conducted a phase 1 study with an adaptive design in which we
gave escalating doses of autologous ATCs expressing a GD2-specific
CAR incorporating the 14g2a single-chain variable fragment and the
CD28 and OX40 costimulatory endodomains (GD2-CAR3)7 to pa-
tients with relapsed or refractory NB. GD2-CAR3 T cells were admin-
istered to three study cohorts (Figure 1). In cohort 1, four consecutive
patients were enrolled; two patients received 1  107 and an addi-
tional two patients received 1 108 GD2-CAR3 T cells intravenously.
In cohort 2, four consecutive patients were enrolled; two patients
received 1  108, and an additional two patients received 1.5  108
GD2-CAR3 T cells intravenously. Patients also received Cy/Flu
with cyclophosphamide at 500 mg/m2/dose on days 4, 3, and
2 and fludarabine 30 mg/m2/dose on days 4 and 3 prior to
CAR T cell administration. In cohort 3, three consecutive patients
were enrolled receiving 1.5  108 GD2-CAR3 T cells intravenously.Molecular Therapy Vol. 25 No 9 September 2017 2221
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hibitor pembrolizumab on days 1 and +21 at 2 mg/kg/dose for
each dose. The detection in preclinical studies of high levels of
PD-1 on GD2 CAR T cells and of PDL1 on IFN-g-exposed neuro-
blasts provided the rationale for the addition of PD-1 inhibition in
this cohort (Figure S7). Clinical evaluation and laboratory testing
were performed on day 0 and at weeks 1, 2, 4, and 6 post-infusion
for all cohorts. In addition, patients receiving Cy/Flu were evaluated
on day 4, and patients receiving pembrolizumab were evaluated at
week 3. All patients were included in primary and safety analyses. The
trial is registered at clinicaltrials.gov (NCT01822652).
Patients
Eligible patients had evaluable relapsed or refractory NB at the time of
cell infusion. Patients had to have adequate organ function, and they
were ineligible if human anti-mouse antibodies were detected or if
they had a history of hypersensitivity to murine proteins. Patients
must have completed previous therapy including other investiga-
tional treatments. Patients with a history of cardiomegaly, bilateral
pulmonary infiltrates, and airway obstruction causing tumors were
excluded, as were patients with HIV seropositivity or Lansky-Karnof-
sky score of less than 60%. Patients assigned to receive Cy/Flu or pem-
brolizumab were excluded if they had a previous history of sensitivity
to these drugs. Patients receiving pembrolizumab had to have normal
thyroid function tests. All participants and/or their legal guardians
provided written informed consent/assent upon enrollment and prior
to administration of the cells.
Clinical Grade Vector Production
GD2-CAR3 was generated as previously described by Pulè et al.7 To
produce the clinical grade vector, the sequence of the iC9 safety
switch18 was cloned in frame, 50 of the GD2-CAR3 gene in the SFG
retroviral backbone (iC9.GD2-CAR3), and a producer cell line was
picked by using PG-13 cells (ATCC CRL-10686) based on the high-
est-titer clone. The transgene integration was confirmed with
sequencing, and the producer cell clone was validated under Good
Manufacturing Practice guidelines. The final viral supplement was
stored at 80C and tested prior to release for clinical testing.
CAR T Cell Manufacturing
iC9.GD2-CAR3 T cells were generated using peripheral blood mono-
nuclear cells (PBMCs) from patients first simulated with CD3
and CD28 (Miltenyi Biotec) mAbs with recombinant human IL-2
(100 U/mL; Prometheus) or IL-7 and IL-15 (10 ng/mL and
5 ng/mL, respectively; R&D Systems) on day 1 and transduced with
retroviral particles encoding the GD2-CAR3 construct in 24-well,
RetroNectin-coated plates (Takara Bio) on day 3. Next, T cells were
washed and replated on day 5, and expanded until numbers were suf-
ficient for testing and patient infusions. Patients in cohort 1 received
T cells expanded with IL-2, which was substituted by IL-7 and IL-15
for patients in cohorts 2 and 3.24 CAR T cell viability, CD4/CD8, and
naive memory/effector subset composition were largely unaffected,
but in vitro cytotoxicity of the GD2+ NB cell line was increased after
this change (Figure S6).2222 Molecular Therapy Vol. 25 No 9 September 2017Real-TimePCR to AssessCARTCell Expansion andPersistence
Evaluation of CAR T cell persistence was assessed by calculating the
copy number of the CAR transgene after extracting genomic DNA
from PBMCs with QIAamp DNA Blood Minikit (QIAGEN) accord-
ing to the manufacturer’s manual and measuring the transgene copy
number with RT-PCR using primers (forward: 50-GCTGCACCA
ACTGTATCCATCTT-30; reverse: 30-GGTCCAGACTGCTGAAG
CT-50) and probe (50-CACCCGACCCACCACC-30) sequences
(Applied Biosystems) in the ABI Prism 7700 Sequence Detector
(PerkinElmer).3 The copy number was normalized to 1 mg of DNA
of PBMCs in the patient samples. Lymphodepleting chemotherapy
with Cy/Flu decreases total WBC, resulting in an artificial increase
of the transgene copy number measured by PCR when normalized
to DNA only; therefore, for the 6 weeks following lymphodepletion,
we instead show transgene copy number per milliliter of peripheral
blood. AUC of CAR T cell persistence was calculated from copy num-
ber per milliliter over time.
Detection of CAR T Cells in Peripheral Blood of Patients
T cells expressing our GD2-CAR3 were detected from peripheral us-
ing 1A7 idiotypic antibody as previously described by Rossig et al.42
Multiplex Assay for Cytokine Levels
Serum cytokine levels were measured with Milliplex MAP magnetic-
bead-basedmulti-analyte panel (EMDMillipore) on the Luminex 200
system (Luminex) with the xPONENT (Luminex) software according
to the manufacturer’s manual.
Immunophenotyping of GD2-CAR3 T Cells and Peripheral Blood
Myeloid Cells
Peripheral blood monocyte subsets were assessed using phy-
coerythrin (PE), FITC, allophycocyanin, allophycocyanin-Cy7 or
PE-Cy7, V500-C, or Pacific Blue-conjugated antibodies specific to
CD45 (2D1), CD163 (GHI/61), CD33 (P67.6), CD11b (D12), HLA-
DR (L243), CD14 (MdP9), CD15 (80H5), and PD-1 (PD1-3) from
BD Biosciences; the region analyzed was first defined, followed by
gating in populations on single color/side scatterplots, and subset
composition was calculated using Boolean methodology after gating.
PD-1 expression of GD2-CAR3 T cells was tested with EH12.1 clone
(BD Horizon), and PD-L1 expression of NB cells was detected with
MIH1 clone (BD Pharmingen) in preclinical studies.
Clinical Response Assessment
Response to therapy was evaluated by 3D imaging (computed tomog-
raphy [CT] or magnetic resonance imaging [MRI]), MIBG scan, and
bone marrow evaluation 6 weeks after initial infusion, according to
the International Neuroblastoma Response Criteria.10 MIBG-positive
lesions were quantified by Curie scoring in the eight patients for
whom pre- and post-infusion imaging were available.43 Bone marrow
was evaluated by standard pathologic testing.
Outcomes
The primary objective of this study was to evaluate the safety of GD2-
CAR3 T cells in patients with relapsed or refractory NB. Secondary
www.moleculartherapy.orgobjectives were to determine their in vivo persistence, antitumor
response rate, and effect on peripheral blood lymphoid and myeloid
cells. Adverse events were monitored according to the NIH Common
Terminology Criteria for Adverse Events (CTCAE) version 4 (https://
ctep.cancer.gov).
Statistical Analysis
All patients were included in primary and safety analyses. Descriptive
statistics were used to describe phenotypic data and T cell expansion.
Plots of growth curves demonstrating measurements over time within
patients were generated to visualize patterns of immune reconstitu-
tion. AUCs were calculated using trapezoidal rule for CAR T cell
frequencies over time for every patient. Comparisons were made
between groups using Wilcoxon rank-sum test or t test, whichever
was appropriate, for continuous variables and the Fisher exact test
for categorical variables. Correlation analysis was performed using
Spearman’s rank correlation coefficient. Survival data were analyzed
by the Kaplan-Meier method. Overall survival (OS) was calculated
from the time of the first GD2-CAR3 T cell infusion to death from
any cause; observations were censored at the date of last follow-up.
Changes from baseline to follow-up measures were compared using
the Wilcoxon signed rank test. Statistics were computed using
GraphPad Prism 6 (GraphPad Software), SAS 9.4 and R 3.3.2. Differ-
ences were considered significant when p < 0.05.
Study Approval
This study was approved by the US Food and Drug Administration,
the Recombinant DNA Advisory Committee of the NIH, and the
Protocol Review Committee, Institutional Biosafety Committee and
Institutional Review Board of Baylor College of Medicine. The study
was conducted in accordance with Declaration of Helsinki principles.
All participants and/or their legal guardians provided written
informed consent/assent upon enrollment and prior to administra-
tion of the cells.
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